197 related articles for article (PubMed ID: 38420011)
1. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
[TBL] [Abstract][Full Text] [Related]
2. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract][Full Text] [Related]
3. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
5. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
[TBL] [Abstract][Full Text] [Related]
6. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
7. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced
Lee ATM; Ou SI
Lung Cancer (Auckl); 2024; 15():75-80. PubMed ID: 38807655
[TBL] [Abstract][Full Text] [Related]
8. Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in
Scattolin D; Scagliori E; Scapinello A; Fantin A; Guarneri V; Pasello G
Front Oncol; 2023; 13():1201599. PubMed ID: 37492479
[TBL] [Abstract][Full Text] [Related]
9. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
10. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract][Full Text] [Related]
11. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
12. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
Gao Q; Su J; Xiao F; Lin X; Yang J
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
[TBL] [Abstract][Full Text] [Related]
13. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
14. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract][Full Text] [Related]
15. Pralsetinib for the treatment of a
Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
Ke JY; Huang S; Jing ZT; Duan MC
Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of selpercatinib in Chinese patients with advanced
Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced
Lu S; Zheng X; Sun Y; Huang D; Wu L; Ji Q; Zhou C; Zhou J; Guo Y; Ge M; Ding D; Shao J; Zhang W; Gao M; Cheng Y
Ther Adv Med Oncol; 2023; 15():17588359231189429. PubMed ID: 37655205
[TBL] [Abstract][Full Text] [Related]
19. Precision oncology with selective RET inhibitor selpercatinib in
Gouda MA; Subbiah V
Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
[TBL] [Abstract][Full Text] [Related]
20. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
